EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12

Sophia A Mahoney iD, Krystyna Mazan-Mamczarz, Dimitrios Tsitsipatis iD, Nicholas S VanDongen, Charnae' Henry-Smith, Ada N Okereke, Rachel Munk, Sanna Darvish, Kevin O Murray iD, Supriyo De, Myriam Gorospe iD, Douglas R Seals und 3 weitere

Aging Cell · 2026

DOI: 10.1111/acel.70500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging Cell, 2026. Verfasst von Sophia A Mahoney und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Physiology, University of Colorado Boulder, Boulder, Colorado, USA. Hauptthemen laut MEDLINE: Flavonols, Chemokine CXCL12, Senescence-Associated Secretory Phenotype, Aging. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, American Heart Association, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advancing age is the strongest risk factor for cardiovascular diseases (CVDs), primarily due to progressive vascular endothelial dysfunction. Cellular senescence and the senescence‐associated secretory phenotype (SASP) contribute to age‐related endothelial dysfunction by promoting mitochondrial oxidative stress and inflammation, which reduce nitric oxide (NO) bioavailability. However, the molecular changes in senescent endothelial cells (ECs) and their role in endothelial dysfunction with aging remain unclear. As such, we sought to identify the EC‐related signaling pathways, endothelial‐associated SASP factors, and their impact on endothelial function with aging. Single‐cell transcriptomics was performed on aortas from young (6mos) and old (27mos) female and male mice with and without in vivo senolytic treatment with fisetin (100 mg/kg/day administered intermittently) to characterize EC senescence and transcript expression changes. Circulating levels of SASP factors were measured to assess systemic changes associated with aging and fisetin treatment. Plasma exposure experiments were conducted in isolated mouse arteries and cultured human aortic ECs to determine the causal role of the circulating SASP milieu and specific SASP factors in mediating endothelial dysfunction and underlying mechanisms of action. Senescent ECs exhibited elevated expression of SASP factors, particularly Cxcl12 , which was reversed by fisetin supplementation, with responses also reflected in circulating CXCL12 concentrations. Plasma from old mice impaired endothelial function by inducing vascular cell senescence, reducing NO, increasing mitochondrial oxidative stress, shifting receptor and promoting endothelial‐to‐mesenchymal transition—effects partially driven by CXCL12 and prevented by fisetin. These results identify the SASP and CXCL12 as drivers of age‐related endothelial dysfunction and establish mechanisms of senolytic intervention with fisetin supplementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlavonolsChemokine CXCL12Senescence-Associated Secretory PhenotypeAgingSenotherapeuticsEndothelial CellsFlavonoidsEndothelium, VascularAnimalsMiceHumansFemaleMaleCellular SenescenceMice, Inbred C57BL

Stichwörter der Autor:innen

CXCL12cellular senescenceendothelial dysfunctionsenolyticsvascular aging

Substanzen

fisetinFlavonolsChemokine CXCL12SenotherapeuticsFlavonoids

Autor:innen und Institutionen

  • Department of Integrative Physiology, University of Colorado Boulder, Boulder, Colorado, USA.
  • Laboratory of Genetics and Genomics, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, Maryland, USA.
  • Laboratory of Cardiovascular Science, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, Maryland, USA.
  • Department of Medicine-Geriatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

ORCID-Profile: Sophia A Mahoney, Dimitrios Tsitsipatis, Kevin O Murray, Myriam Gorospe

Förderung

  • NHLBI NIH HHS
  • American Heart Association
  • NIA NIH HHS
  • NIDDK NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institute on Aging
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Mahoney, S. A., Mazan-Mamczarz, K., Tsitsipatis, D., VanDongen, N. S., Henry-Smith, C., Okereke, A. N., Munk, R., Darvish, S., Murray, K. O., De, S., Gorospe, M., Seals, D. R., Rossman, M. J., Herman, A. B., & Clayton, Z. S. (2026). Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12. Aging Cell. https://doi.org/10.1111/acel.70500

Vancouver

Mahoney SA, Mazan-Mamczarz K, Tsitsipatis D, VanDongen NS, Henry-Smith C, Okereke AN, et al. Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12. Aging Cell. 2026. doi:10.1111/acel.70500

BibTeX
@article{Mahoney2026,
  author = {Mahoney, Sophia A and Mazan-Mamczarz, Krystyna and Tsitsipatis, Dimitrios and VanDongen, Nicholas S and Henry-Smith, Charnae' and Okereke, Ada N and Munk, Rachel and Darvish, Sanna and Murray, Kevin O and De, Supriyo and Gorospe, Myriam and Seals, Douglas R and Rossman, Matthew J and Herman, Allison B and Clayton, Zachary S},
  title = {Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12},
  journal = {Aging Cell},
  year = {2026},
  doi = {10.1111/acel.70500}
}
Kostenlos starten →